Other substances

Ivermectin

A macrocyclic lactone antiparasitic and potential anti-viral.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

17
 Supporting references
0
 Contradictory references
119
 AI-suggested references
83
 Clinical trials

General information

Ivermectin is an orally bioavailable antiparasitic and potential anti-viral. It activates nematode glutamate-gated chloride channels. This leads to the paralysis and death of the parasite. Ivermectin may possess anti-SARS-CoV-2 activity via inhibition of nuclear import of host and viral proteins and might inhibit viral replication (Caly et al., 2020; NCIt). It was also observed to inhibit the SARS-CoV-2 3C-like protease in vitro (Mody et al., 2021) but with potentially high cytotoxicity (Jan et al., 2021). Ivermectin is It is listed in the World Health Organization Model List of Essential Medicines.

A large double-blind, randomized, placebo-controlled clinical trial TOGETHER found no benefit of ivermectin in COVID-19 patients with at least one risk factor of disease progression (Reis et al., 2022).

Ivermectin on DrugBank
Ivermectin on PubChem
Ivermectin on Wikipedia

Synonyms

Ivermectin B1a

Marketed as

ASCAPIL; DETEBENCIL; ERMETIN; GOTAX; IMECTIN; IVECTIN; IVERA; IVERGOT; IVERMEC; IVEXTERM; IVORI; KAONOL; KILOX; MAIKEDING; QUANOX; REVECTINA; ROSIVER; SCABO; SCAVISTA; SECURO; SKLICE; SOOLANTRA; STROMECTOL; VERMECTIN

 

Structure image - Ivermectin

CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C

Supporting references

Link Tested on Impact factor Notes Publication date
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Vero/hSLAM cells Apr/03/2020
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
Preprint 		Patients

Add-on use of ivermectin to hydroxychloroquine and azithromycin had better effectiveness, shorter hospital stay, and relatively safe compared with controls

 Jul/08/2020
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2
Spike protein ACE2 Small molecule In silico 		in silico 1.59

Predicted to bind the interface between the SARS-CoV-2 spike protein and the host ACE2 receptor.

 Sep/01/2020
Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach
RdRpol Small molecule In silico 		in silico 5.16

Predicted to bind the SARS-CoV-2 RNA-dependent RNA polymerase.

 Sep/17/2020
Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)
Small molecule 		Patients 8.31

Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement

 Oct/12/2020
Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment
Small molecule In vitro 		in silico analysis of proteomic data 5.55

At the proteomic level, ivermectin treatment elicits in vitro cellular response that could be beneficial in treatment of SARS-CoV-2 infection.

 Sep/22/2020
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches
Spike protein Small molecule In silico 		in silico 3.22

Predicted to inhibit the SARS-CoV-2 spike protein binding to the host's ACE2 receptor.

 Sep/24/2020
An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α
nsp9 Small molecule In silico 		in silico 3.22

Predicted to bind the SARS-CoV-2 nsp9 protein.

 Nov/02/2020
Step toward repurposing drug discovery for COVID‐19 therapeutics through in silico approach
Spike protein 3CLpro PapainLpro RdRpol nsp3 nsp16 nsp9 nsp10 nsp4 Helicase (nsp19) Small molecule In silico 		in silico 1.90

Predicted to bind SARS-CoV-2 Papain-like protease.

 Nov/10/2020
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Small molecule Randomized controlled double-blind trial Mild severity 		Patients 3.20

Earlier virological clearance in treated mild COVID-19 patients compared to placebo. Improvement of inflammatory markers observed at day 7, as well. No significant difference between clinical symptoms (fever, cough, or sore throat) observed, however. Ivermectin treatment was safe. Sample size: 22 + 23 placebo. Dosage: 12 mg daily for 5 days. Endpoints: The time required for virological clearance; remission of fever and cough within 7 days (primary).



 Dec/02/2020
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
Small molecule Moderate severity Mild severity Cohort study 		Patients 4.96

Significantly lower number of ivermectin treated patients required antibiotic treatment, supplementary oxygen, intensive care management, or developed respiratory distress. Faster negative viral conversion, lower mortality and shorted duration of hospital stay was observed, as well. The therapy was well tolerated. Sample size: 115 + 133 control. Dosage: 12 mg single dose.


 Sep/24/2020
Use of ivermectin in the treatment of Covid-19: A pilot trial
Small molecule Randomized controlled open trial 		Patients 4.14

There was a slight trend towards faster second consecutive negative SARS-CoV-2 test in patients with higher ivermectin dosage compared to control. The small sample size was a limitation of the study. Sample size: 7 (400 μg/kg) + 14 (200 μg/kg) + 6 (100 μg/kg) + 4 control. Dosage: A cumulative dose of 100, 200, or 400 μg/kg. Primary outcome: The proportion of SARS-CoV-2 negative patients during 7-day follow-up.



 Mar/09/2021
Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection
3CLpro PapainLpro Enzyme assay Animal model In vitro In silico 		in silico; in vitro enzyme assay; Vero E6 cells; golden Syrian hamsters; SARS-CoV-2 clinical isolate hCoV-19/Taiwan/4/2020 9.41

Inhibited SARS-CoV-2 infection in Vero E6 cells but displayed high cytotoxicity.

 Jan/15/2021
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay

Potently inhibits (IC50 of 21.5 µM; 85% inhibition at 50 µM) the SARS-CoV-2 3C-like protease in vitro.

 Jan/20/2021
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos
Small molecule Randomized controlled double-blind trial Moderate severity Mild severity 		Patients 2.53

Ivermectin administration statistically significantly reduced the number of days to SARS-CoV-2 negativity compared to the control, with the effect being more potent in the 12 mg regime group than in the 6 mg regime group. A significant improvement was also observed in the platelet count. No adverse effects were noted. Sample size: 21 (6 mg regimen) + 21 (12 mg regimen) + 20 placebo. Dosage: 6 mg (in 6 mg regimen group) or 12 mg (in 12 mg regimen group) every 84 hours for two weeks. Primary endpoint: The number of days to SARS-CoV-2 negativity.



 Feb/18/2021
Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19
Small molecule Non-randomized controlled open trial Phase I clinical trial Mild severity 		Mild COVID-19 patients 2.02

In combination with ribavirin, nitazoxanide, and zinc supplementation. Observed improvement in SARS-CoV-2 nasopharyngeal viral clearance at days 7 and 15 compared to control. Sample size: 62 + 51 control. Dosage: 18 mg (≤90 kg body w.) or 24 mg (90-120 kg body w.) or 30 mg (≥120 kg body w.) every 72 hours for two weeks.

 Feb/16/2021
Ivermectin reduces in vivo coronavirus infection in a mouse experimental model
Small molecule Animal model 		mouse hepatitis virus; BALB/c mice 4.00

Indirect evidence: The drug lowered viral load and alleviated signs of disease in a mouse model challenged with mouse hepatitis virus, which is a type 2 family RNA coronavirus similar to SARS-CoV-2.

 Mar/30/2021

AI-suggested references

Link Publication date
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial.
Jul/23/2021
Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
Oct/05/2021
Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection.
Feb/02/2022
The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness.
Jan/18/2022
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
Jul/16/2021
Identification of Main Protease of Coronavirus SARS-CoV-2 (Mpro) Inhibitors from Melissa officinalis.
Mar/01/2021
SIT1 transporter as a potential novel target in treatment of COVID-19.
Jul/13/2021
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Feb/20/2021
In silico evaluation of food-derived carotenoids against SARS-CoV-2 drug targets: Crocin is a promising dietary supplement candidate for COVID-19.
Oct/22/2020
Pharmacotherapy for SARS-CoV-2 and Seizures for drug repurposing presumed on Mechanistic Targets.
Apr/14/2022
Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).
Aug/07/2020
Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience.
Jun/14/2021
In Vitro Data of Current Therapies for SARS-CoV-2.
Jun/24/2020
Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis.
Dec/31/2021
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
Nov/17/2020
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Oct/07/2020
Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action
May/27/2020
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19.
Dec/01/2020
Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.
May/06/2021
Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin
May/11/2020
Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Nov/03/2020
Intravenous veterinary ivermectin in a COVID-19 patient causing neurotoxicity
Feb/07/2022
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
Apr/27/2020
Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2
Apr/06/2021
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.
Oct/13/2020
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Nov/18/2021
Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications
Jun/30/2020
Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients
Oct/15/2021
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching
Jan/15/2022
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Oct/21/2020
Antivirals that target the host IMPalpha/beta1-virus interface
Sep/01/2020
Pharmacokinetics and safety of inhaled ivermectin in mice as a potential COVID-19 treatment
Apr/20/2021
Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells
May/01/2021
On a knife's edge of a COVID-19 pandemic: is containment still possible?
Mar/09/2020
Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus
Dec/01/2021
In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
Mar/25/2021
Molecular docking and dynamics studies of curcumin with COVID-19 proteins.
Jun/10/2021
Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment
Mar/21/2020
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients
Nov/11/2020
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19
Jun/07/2020
Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.
Mar/11/2022
The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.
Apr/06/2021
Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment
Jun/13/2020
PAK1-blockers: Potential Therapeutics against COVID-19
Aug/11/2021
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2.
Jan/25/2021
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response
Sep/14/2021
Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19
Jun/30/2021
Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model
Mar/16/2022
Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection
Apr/15/2020
Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2.
Jun/03/2020
Safety and Efficacy of a MEURI Program for the Use of High Dose Ivermectin in COVID-19 Patients
Feb/22/2022
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
Mar/04/2021
An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin alpha
Mar/18/2022
Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques
Aug/20/2020
Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics
Sep/08/2021
Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model
Jan/23/2021
Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication
Oct/20/2021
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
May/26/2021
Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
Jun/14/2021
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial
Jan/06/2022
Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.
May/28/2021
Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin
Jul/12/2021
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
May/04/2021
Old and re-purposed drugs for the treatment of COVID-19
Jun/01/2020
Ilimaquinone (marine sponge metabolite) as a novel inhibitor of SARS-CoV-2 key target proteins in comparison with suggested COVID-19 drugs: designing, docking and molecular dynamics simulation study
Oct/13/2020
Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters
Dec/09/2021
Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial
Mar/03/2022
Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening
Jun/02/2020
Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.
Aug/11/2021
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
Apr/10/2020
Safety profile of COVID-19 drugs in a real clinical setting
Oct/06/2021
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness.
Dec/02/2020
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
Feb/10/2021
Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.
Jul/23/2021
Protective effect of vitamin C against ivermectin induced nephrotoxicity in different age groups of male wistar rats: bio-histopathological study
Feb/07/2020
Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study
Jun/07/2021
Repurposing the drug, ivermectin, in COVID-19: toxicological points of view
Feb/05/2022
Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases
Nov/05/2021
The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.
Apr/12/2021
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Apr/30/2021
White paper on Ivermectin as a potential therapy for COVID-19.
Aug/18/2020
Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19.
Sep/28/2020
Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
Jul/09/2020
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.
Jul/07/2021
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
Oct/29/2021
Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches
Apr/07/2022
Elucidation of the inhibitory activity of ivermectin with host nuclear importin alpha and several SARS-CoV-2 targets
Jan/21/2022
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
Jul/02/2021
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
Jun/14/2020
Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
Mar/30/2021
Effectiveness and safety of Ivermectin in COVID-19 patients: A prospective study at a safety-net hospital
Jul/27/2021
Comparative study of the interaction of ivermectin with proteins of interest associated with SARS-CoV-2: A computational and biophysical approach.
Aug/19/2021
Evaluation of ivermectin antiviral activity against avian infectious bronchitis virus using a chicken embryo model
Jan/06/2021
Antiviral treatment of COVID-19
Jul/12/2021
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial
May/14/2021
Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats.
Oct/13/2020
Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers.
Aug/05/2021
Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral gene Orf9c on human pluripotent stem cell-derived cardiomyocytes
Feb/17/2022
Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19
Jun/15/2021
Ivermectin: Potential Role as Repurposed Drug for COVID-19.
Aug/19/2020
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
Mar/23/2022
From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Jan/03/2022
Antivirals virtual screening to SARS-CoV-2 non-structural proteins
May/05/2021
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
Aug/25/2021
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
Feb/16/2021
Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis
Jul/04/2021
Multi-drug Treatment for COVID-19-induced Acute Respiratory Distress Syndrome
Feb/28/2022
Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules
Apr/19/2022
Ivermectin for preventing and treating COVID-19
Jul/28/2021
Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study.
Aug/26/2021
Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons.
Mar/31/2021
Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants
Mar/17/2021
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches
Nov/01/2020
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Feb/01/2022
The in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus
Mar/31/2021
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
Jan/28/2022
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial.
Apr/20/2021
Blocking the interactions between human ACE2 and coronavirus spike glycoprotein by selected drugs: a computational perspective
Apr/01/2022
SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies
Nov/19/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05283954 Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea Not yet recruiting Phase 2|Phase 3 May/01/2022 Jul/30/2022
  • Alternative id - Fluo-Pred-Iver
  • Interventions - Drug: Combination regimen: Fluoxetine, Prednisolone, Ivermectin|Drug: Combination regimen: Albendazole, Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 954
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - COVID-19 disease progression|SARS-CoV-2 viral load|COVID-19 WHO Clinical progression scale score|Adverse Events
NCT04425707 Ivermectin In Treatment of COVID 19 Patients Recruiting Not Applicable Jun/09/2020 Sep/01/2020
  • Alternative id - 14-2020/3
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - isolation and referal hospitals for COVID 19 patients, Cairo, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - to evaluate the role of Ivermectin as a line of treatment for COVID 19|To asses the rate of viral clearance in comparison to other treatment protocols.
NCT04530474 Outpatient Use of Ivermectin in COVID-19 Withdrawn Phase 3 Apr/01/2021 Jun/30/2021
  • Alternative id - 1285242
  • Interventions - Drug: Ivermectin Pill|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Temple University Hospital, Philadelphia, Pennsylvania, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Improvement
NCT04591600 Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients Completed Phase 1|Phase 2 Jul/01/2020 Oct/14/2020
  • Alternative id - IVM-DOX
  • Interventions - Drug: Ivermectin and Doxycyline|Drug: Standard of care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Akarkh Healt hdirectorate, Baghdad, Iraq
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 140
  • Age - 16 Years to 86 Years   (Child, Adult, Older Adult)
  • Outcome measures - Mortality rate|Rate of progression disease|Time to recovery
NCT04551755 Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19 Not yet recruiting Phase 2 Sep/01/2020 Dec/01/2020
  • Alternative id - 31211062020
  • Interventions - Drug: Ivermectin and Doxycycline|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 188
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to outcome measure of fever (<100.40F)and cough|Negative RT-PCR test on day 5 of treatment
NCT02735707 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting Phase 3 Apr/11/2016 Dec/01/2025
  • Alternative id - U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584
  • Interventions - Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Standard course macrolide|Drug: Extended course macrolide|Other: No systemic corticosteroid|Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Fixed-duration higher dose Hydrocortisone|Other: No antiviral agent for influenza|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Other: No antiviral agent for COVID-19|Drug: Lopinavir / Ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Ivermectin|Other: No immune modulation for COVID-19|Drug: Interferon beta-1a|Drug: Anakinra|Drug: Tocilizumab|Drug: Sarilumab|Drug: Local standard venous thromboprophylaxis|Drug: Therapeutic anticoagulation|Drug: Conventional low dose thromboprophylaxis|Drug: Intermediate dose thromboprophylaxis|Drug: Continuation of therapeutic dose anticoagulation|Other: No immunoglobulin|Biological: Convalescent plasma|Biological: Delayed administration of convalescent plasma|Other: No vitamin C|Drug: Vitamin C|Other: No antiplatelet|Drug: Aspirin|Drug: P2Y12 inhibitor|Other: No simvastatin|Drug: Simvastatin|Other: Placebo|Drug: Eritoran|Drug: Apremilast|Procedure: Clinician-preferred mechanical ventilation strategy|Procedure: Protocolised mechanical ventilation strategy|Other: No renin-angiotensin system inhibitor|Drug: Angiotensin converting enzyme inhibitor|Drug: Angiotensin Receptor Blockers|Drug: ARB + DMX-200|Other: No cysteamine|Drug: Cysteamine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Florida, Jacksonville, Florida, United States|Augusta University, Augusta, Georgia, United States|University of Illinois Health, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States|Brown University - Rhode Island Hospital, Providence, Rhode Island, United States|Canberra Hospital, Canberra, Australian Capital Territory, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Sutherland Hospital, Caringbah, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Dubbo Base Hospital, Dubbo, New South Wales, Australia|Northern Beaches Hospital, Frenchs Forest, New South Wales, Australia|Nepean Hospital, Kingswood, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|John Hunter Hospital, Newcastle, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Prince Charles Hospital, Brisbane, Queensland, Australia|Mater Hospital Brisbane, Brisbane, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Caboolture Hospital, Caboolture, Queensland, Australia|Queen Elizabeth II Jubilee Hospital, Coopers Plains, Queensland, Australia|Logan Hospital, Logan, Queensland, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|Townsville Hospital, Townsville, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Lyell McEwin Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Launceston Hospital, Launceston, Tasmania, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|Casey Hospital, Berwick, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Dandenong Hospital, Dandenong, Victoria, Australia|Angliss Hospital, Ferntree Gully, Victoria, Australia|Footscray Hospital, Footscray, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Sunshine Hospital, Sunshine, Victoria, Australia|Werribee Mercy Hospital, Werribee, Victoria, Australia|St John of God Hospital Midland, Midland, Western Australia, Australia|St John of God Hospital Murdoch, Murdoch, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Subiaco, Subiaco, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Foothills Medical Centre, Calgary, Alberta, Canada|Peter Lougheed Centre, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada|Royal Alexandra Hospital, Alberta, Edmonton, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Surrey Memorial Hospital, Surrey, British Columbia, Canada|St Boniface General Hospital, Winnipeg, Manitoba, Canada|Health Sciences Centre Winnipeg, Winnipeg, Manitoba, Canada|Grace Hospital, Winnipeg, Manitoba, Canada|Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick, Canada|The Moncton Hospital, Fredericton, New Brunswick, Canada|The Saint John General Hospital, Fredericton, New Brunswick, Canada|William Osler Health System, Brampton, Ontario, Canada|Brantford General Hospital, Brantford, Ontario, Canada|Hamilton general Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|St Mary's General Hospital, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Niagara Health, Saint Catharines, Ontario, Canada|Thunder Bay General Hospital, Thunder Bay, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|St Joseph's Health Centre, Toronto, Ontario, Canada|CIUSS Chaudieres-Appalaches (Levis), Lévis, Quebec, Canada|Hospital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Hôpital Fleury, Montréal, Quebec, Canada|Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montréal, Quebec, Canada|CHU de Québec - Université Laval, Québec, Quebec, Canada|IUCPQ-UL, Québec, Quebec, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Saskatoon, Saskatchewan, Canada|Universidad de La Sabana, Chía, Cundinamarca, Colombia|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Apollo Main Hospital, Chennai, Tamil Nadu, India|Apollo First Med Hospital, Chennai, Tamil Nadu, India|Apollo Vanagaram Hospital, Chennai, Tamil Nadu, India|Apollo Speciality Hospital - OMR, Chennai, Tamil Nadu, India|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|St. Marianna University Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan|Saiseikai Kumamoto Hospital, Minami, Kumamoto, Japan|Osaka City General Hospital, Osaka, Japan|Nerima Hikarigaoka Hospital, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Itabashi Chuo Medical Center, Tokyo, Japan|Tokyo bay Urayasu-Ichikawa Medical Center, Tokyo, Japan|Wakayama Medical University, Wakayama, Japan|Chitwan Medical College, Bharatpur, Nepal|Grande International Hospital, Kathmandu, Nepal|Hospital for Advanced Medicine and Surgery (HAMS), Kathmandu, Nepal|Nepal Mediciti, Kathmandu, Nepal|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Taranaki Base Hospital, New Plymouth, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Ziauddin University Hospital Clifton Campus, Karachi, Sindh, Pakistan|Abbasi Shaheed Hospital, Karachi, Sindh, Pakistan|National Institute of Cardiovascular Diseases, Karachi, Karachi, Sindh, Pakistan|South City Hospital, Karachi, Karachi, Sindh, Pakistan|Ziauddin University North Nazimabad Campus, Karachi, Sindh, Pakistan|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases "Dr. Victor Babes", Bucharest, Romania|King Abdulaziz Medical City, Riyadh, Saudi Arabia|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basildon Hospital, Basildon, England, United Kingdom|Basingstoke and North Hampshire Hospital, Basingstoke, England, United Kingdom|Royal United Hospital, Bath, Bath, England, United Kingdom|Queen Elizabeth Hospital Birmingham, Birmingham, England, United Kingdom|Birmingham City Hospital, Birmingham, England, United Kingdom|Blackburn Hospital, Blackburn, England, United Kingdom|Pilgrim's Hospital, Boston, England, United Kingdom|Royal Bournemouth Hospital, Bournemouth, England, United Kingdom|Royal Sussex County Hospital, Brighton, England, United Kingdom|Southmead Hospital, Bristol, England, United Kingdom|Bristol Royal Hospital, Bristol, England, United Kingdom|Queen's Hospital, Burton, Burton on Trent, England, United Kingdom|Royal Papworth Hospital, Cambridge, England, United Kingdom|Addenbrookes Hospital, Cambridge, England, United Kingdom|Cumberland Royal Infirmary, Carlisle, England, United Kingdom|Ashford & St Peters Hospital Trust, Chertsey, England, United Kingdom|Chesterfield Royal Hospital, Chesterfield, England, United Kingdom|Countess of Chester Hospital, Chester, England, United Kingdom|Colchester Hospital, Colchester, England, United Kingdom|University Hospital Coventry, Coventry, England, United Kingdom|North Manchester General Hospital, Crumpsall, England, United Kingdom|Darlington Memorial Hospital, Darlington, England, United Kingdom|Darent Valley Hospital, Dartford, England, United Kingdom|Russells Hall Hospital, Dudley, England, United Kingdom|University Hospital of North Durham, Durham, England, United Kingdom|Royal Devon and Exeter Hospital, Exeter, England, United Kingdom|Frimley Park Hospital, Frimley, England, United Kingdom|Queen Elizabeth Hospital, Gateshead, England, United Kingdom|Medway Maritime Hospital, Gillingham, England, United Kingdom|James Paget Kings Lynn Hospital, Great Yarmouth, England, United Kingdom|Royal Surrey County Hospital, Guildford, England, United Kingdom|Northwick Park Hospital, Harrow, England, United Kingdom|Hereford County Hospital, Hereford, England, United Kingdom|Barnet Hospital, High Barnet, England, United Kingdom|Huddersfield Hospital, Huddersfield, England, United Kingdom|King George Hospital, Ilford, England, United Kingdom|Ipswich Hospital, Ipswich, England, United Kingdom|Kettering Hospital, Kettering, England, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Glenfield Hospital, Leicester, England, United Kingdom|Lincoln County Hospital, Lincoln, England, United Kingdom|Liverpool Heart and Chest Hospital, Liverpool, England, United Kingdom|Alder Hey Hospital, Liverpool, England, United Kingdom|Royal Liverpool Hospital, Liverpool, England, United Kingdom|University Hospital Aintree, Liverpool, England, United Kingdom|Croydon University Hospital, London, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Whipps Cross Hospital, London, England, United Kingdom|Newham Hospital, London, England, United Kingdom|St Barts Hosptial, London, England, United Kingdom|North Middlesex Hospital, London, England, United Kingdom|Royal Free Hospital, London, England, United Kingdom|St Thomas' Hospital, London, England, United Kingdom|Guy's Hospital, London, England, United Kingdom|King's College Hospital, London, England, United Kingdom|St George's Hospital, London, England, United Kingdom|Royal Marsden Hospital, London, England, United Kingdom|Ryal Brompton, London, England, United Kingdom|Hammersmith Hospital, London, England, United Kingdom|St Mary's Hospital, London, England, United Kingdom|Charing Cross Hospital, London, England, United Kingdom|Luton and Dunstable University Hospital, Luton, England, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, England, United Kingdom|Manchester Royal Infirmary, Manchester, England, United Kingdom|The Christie Hospital, Manchester, England, United Kingdom|Wythenshawe Hospital, Manchester, England, United Kingdom|Queen Elizabeth Hospital, Woolwich, Margate, England, United Kingdom|The James Cook University Hospital, Middlesbrough, England, United Kingdom|Milton Keynes University Hospital, Milton Keynes, England, United Kingdom|Royal Victoria Infirmary, Newcastle, Newcastle, England, United Kingdom|Newcastle Freeman Hospital, Newcastle, England, United Kingdom|Northampton General Hospital, Northampton, England, United Kingdom|Norfolk and Norwich University Hospital, Norwich, England, United Kingdom|City Hospital Nottingham, Nottingham, England, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, England, United Kingdom|George Eliot Hospital, Nuneaton, England, United Kingdom|Royal Oldham Hospital, Oldham, England, United Kingdom|Princess Royal University Hospital, Orpington, England, United Kingdom|John Radcliffe Hospital, Oxford, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, England, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, England, United Kingdom|Whiston Hospital, Prescot, England, United Kingdom|Royal Preston Hospital, Preston, England, United Kingdom|Royal Berkshire Hospital, Reading, England, United Kingdom|Alexandra Hospital, Redditch, Redditch, England, United Kingdom|Queen's Hospital Romford, Romford, England, United Kingdom|Rotherham General Hospital, Rotherham, England, United Kingdom|Salford Royal Hospital, Salford, England, United Kingdom|Salisbury District Hospital, Salisbury, England, United Kingdom|Royal Hallamshire Hospital, Sheffield, England, United Kingdom|Northern General Hospital, Sheffield, England, United Kingdom|Wexham Park Hospital, Slough, England, United Kingdom|South Tyneside District Hospital, South Shields, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Stepping Hill Hospital, Stockport, England, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, England, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, England, United Kingdom|Sunderland Hospital, Sunderland, England, United Kingdom|King's Mill Hospital, Sutton In Ashfield, England, United Kingdom|Great Western Hospital, Swindon, England, United Kingdom|Western General Hospital, Swindon, England, United Kingdom|Musgrove Park Hospital, Taunton, England, United Kingdom|Torbay and South Devon Hospital, Torquay, England, United Kingdom|Royal Cornwall Hospital, Truro, England, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, England, United Kingdom|Harefield Hospital, Uxbridge, England, United Kingdom|Watford General Hospital, Watford, England, United Kingdom|Southend University Hospital, Westcliff-on-Sea, England, United Kingdom|West Cumberland Hospital, Whitehaven, England, United Kingdom|Royal Albert Edward Infirmary, Wigan, England, United Kingdom|Royal Hampshire Hospital, Winchester, England, United Kingdom|Arrow Park Hospital, Wirral, England, United Kingdom|New Cross Hospital, Wolverhampton, England, United Kingdom|Worcester Royal Hospital, Worcester, England, United Kingdom|York Hospital, York, England, United Kingdom|York Hospital, York, England, United Kingdom|Antrim Area Hospital, Antrim, Northern Ireland, United Kingdom|Royal Victoria Hospital, Belfast, Belfast, Northern Ireland, United Kingdom|Mater Hospital, Belfast, Northern Ireland, United Kingdom|Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|Altnagelvin Hospital, Derry, Northern Ireland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom|Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom|Queen Elizabeth University Hospital, Glasgow, Glasgow, Scotland, United Kingdom|Royal Alexandra Hospital, Glasgow, Paisley, Scotland, United Kingdom|Neville Hall Hospital, Abergavenny, Wales, United Kingdom|Glan Clywd Hospital, Bodelwyddan, Wales, United Kingdom|Princess of Wales Hospital, Bridgend, Wales, United Kingdom|University Hospital of Wales, Cardiff, Wales, United Kingdom|Glangwilli Hospital, Carmarthen, Wales, United Kingdom|Grange University Hospital, Cwmbran, Wales, United Kingdom|Royal Gwent Hospital, Newport, Wales, United Kingdom|Royal Glamorgan Hospital, Pontyclun, Wales, United Kingdom|Morriston Hospital, Swansea, Wales, United Kingdom|Wrexham Maelor Hospital, Wrexham, Wales, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 10000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality|Days alive and not receiving organ support in ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization|World Health Organisation 8-point ordinal scale outcome
NCT04832945 SARS-CoV-2 Pre-exposure Prophylaxis With Ivermectin Retrospective Cohort Study Completed Jun/29/2020 Apr/10/2021
  • Alternative id - 8953
  • Interventions - Drug: Ivermectin 6 Mg Oral Tablet
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Centro Medico Bournigal, Puerto Plata, Dominican Republic|Centro Médico Punta Cana, Punta Cana, Dominican Republic
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 713
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of participants RT-PCR positive for Covid-19|Number of sick participants who condition deteriorated|Number of sick participants who died
NCT04668469 Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic Completed Not Applicable Jun/08/2020 Oct/30/2020
  • Alternative id - Re96.2020
  • Interventions - Drug: Ivermectin|Drug: Hydroxychloroquine|Behavioral: personal protective Measures
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Benha Faculty of Medicine, Benha University, Banhā, Qaluopia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - number of participants with improvement of clinical condition (symptoms and signs)|Reduction of recovery time, hospital stay days and mortality rate|improvement of laboratory investigations and 2 consecutive negative PCR tests taken at least 48 hours apart.
NCT04472585 Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Recruiting Phase 1|Phase 2 Nov/14/2020 Oct/30/2021
  • Alternative id - SZMC/IRB/Internal/215/2020
  • Interventions - Drug: Ivermectin Injectable Solution|Other: Injectable Placebo|Drug: Zinc|Drug: Placebo empty capsule|Drug: Oral Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ali Clinic, Lahore, MA, Pakistan|Shaikh Zayed Hospital, Lahore, Punjab, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 180
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - qRT-PCR|Time taken for alleviation of symptoms|Severity of symptoms|Morality
NCT04703205 Study in COvid-19 Patients With iveRmectin (CORVETTE-01) Active, not recruiting Phase 2 Sep/16/2020 May/31/2022
  • Alternative id - CORVETTE-01
  • Interventions - Drug: Ivermectin 3 MG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Kitasato University, Sagamihara, Kanagawa, Japan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 214
  • Age - 20 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) Period until the COVID-19 PCR test (SARS-CoV-2 nucleic acid detection) becomes negative
NCT04343092 Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management Completed Phase 1 Apr/18/2020 Jun/01/2020
  • Alternative id - PRO20040001
  • Interventions - Drug: Ivermectin (IVM)
  • Study type - Interventional
  • Study results - Has Results
  • Locations - General Directorate of Medical City, Bagdad, Baghdad, Iraq
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 16
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Cured Patients|Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group
NCT04716569 Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19 Recruiting Phase 2|Phase 3 Jan/20/2021 Mar/20/2021
  • Alternative id - SVU MED CIT0 23 4 21 1 120
  • Interventions - Drug: intranasal ivermectin spray
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Zaky Aref, Qinā, Qina, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - progression of covid 19 clinical picture
NCT04392713 Efficacy of Ivermectin in COVID-19 Recruiting Not Applicable Apr/15/2020 Jul/01/2020
  • Alternative id - IVE-COV
  • Interventions - Drug: Ivermectin 6 MG Oral Tablet (2 tablets)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Combined Military Hospital Lahore, Lahore, Punjab, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 15 Years to 65 Years   (Child, Adult, Older Adult)
  • Outcome measures - Negative PCR|Need for mechanical ventilation
NCT04445311 Ivermectin in Treatment of COVID-19 Recruiting Phase 2|Phase 3 May/31/2020 Aug/15/2020
  • Alternative id - ZU-IRB#6151/31-5-2020
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Waheed Shouman, Zagazig, Sharkia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - time to be symptoms free|hospitalization|Mechanical ventilation|length of stay|mortality
NCT04422561 Prophylactic Ivermectin in COVID-19 Contacts Completed Phase 2|Phase 3 May/31/2020 Jul/27/2020
  • Alternative id - ZU-IRB#6150/31-5-2020
  • Interventions - Drug: Ivermectin Tablets
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Zagazig University, Zagazig, Sharkia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 340
  • Age - 16 Years to 70 Years   (Child, Adult, Older Adult)
  • Outcome measures - Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID
NCT04746365 Ivermectin Role in Covid-19 Clinical Trial Completed Phase 4 Dec/06/2020 Feb/06/2021
  • Alternative id - 1029076|2101001
  • Interventions - Drug: ivermectin|Drug: hydroxychloroquine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Shebin-Elkom teaching hospital, Shibīn Al Kawm, Menoufia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Reduction in the WHO ordinal scale of clinical status by at least two points|Time to discharge|Mortality
NCT04403555 Ivermectin as a Novel Therapy in COVID-19 Treatment Completed Phase 2|Phase 3 Jun/01/2020 Dec/01/2020
  • Alternative id - tanta covid treatment
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sherief Abd-Elsalam, Tanta, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 164
  • Age - Child, Adult, Older Adult
  • Outcome measures - The number of patients with mortality|Length of hospital stay|The need for mechanical ventilation
NCT04891250 The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19 Withdrawn Phase 4 Oct/01/2021 Jun/01/2022
  • Alternative id - ZIT
  • Interventions - Drug: Ivermectin|Other: Prophylaxis
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Zambia, Lusaka, Zambia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - All-cause COVID-19 related mortality|COVID-19 Infection|Patient cure rate|Participant Infection Rate
NCT04431466 A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19 Terminated Phase 2 Jul/01/2020 Dec/01/2020
  • Alternative id - IFORS
  • Interventions - Drug: Ivermectin|Other: Standard of Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Univeristário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil|Hospital Universitário da Universidade Federal de São Carlos (HU-UFSCar), São Carlos, São Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 32
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Undetectable viral load during 7 days of follow-up.|Viral load variation in the nasopharyngeal swab.|Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab.|Incidence of Treatment-Emergent Self-reported Adverse Events|Incidence of Treatment-Emergent Laboratory-based Adverse Events
NCT04836299 Clinical Trial to "Study the Efficacy and Therapeutic Safety of Ivermectin: (SAINTBO) Not yet recruiting Phase 2 May/08/2021 Dec/05/2021
  • Alternative id - RCT01
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Universidad Mayor de San Simón, Cochabamba, Bolivia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 90
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Evolution of viral load|Clinical remission|Clinical signs of toxicity
NCT04959786 MANS-NRIZ Trial for COVID-19 Treatment : Extension Study Recruiting Phase 2|Phase 3 Apr/01/2021 Dec/01/2022
  • Alternative id - mu-med-2020-26
  • Interventions - Drug: Ivermectin,ribavirin ,nitazoxanide and zinc
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mansoura University Hospital, Mansoura, Select A State Or Province, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Stabilization of oxygen|In-hospital and 28-day mortality|Negative conversion of SARS-CoV- 2 by Day 28|Time to clinical improvement
NCT04632706 Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19 Completed Phase 1 Sep/22/2020 Mar/09/2021
  • Alternative id - mdc-TTG-CT-001
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester, Greater Mancherster, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other
  • Enrollment - 24
  • Age - 18 Years to 45 Years   (Adult)
  • Outcome measures - Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax])|Pharmacokinetic Concentrations - (Time to Reach Cmax [Tmax])|Pharmacokinetic Concentrations - (Area Under the Plasma Concentration-time Curve From Zero to 24 Hours [AUC0-24hr])|Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2])|Safety and Tolerability - Treatment Emergent Adverse Events (TEAEs)
NCT04944082 Remdesivir- Ivermectin Combination Therapy in Severe Covid-19 Not yet recruiting Phase 4 Jul/01/2021 Dec/31/2021
  • Alternative id - Remdesivir-Ivermectin
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - 1- Improvement in level of oxygenation|2- Need for ventilator support|3- Length of hospital stay|4- Development of complication|5- Mortality
NCT04920942 Ivermectin Treatment Efficacy in Covid-19 High Risk Patients Completed Phase 3 May/31/2021 Oct/31/2021
  • Alternative id - I-TECH21
  • Interventions - Drug: Ivermectin 0.4mg/kg/day for 5 days
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sultanah Aminah Hospital, Johor Bahru, Johor, Malaysia|Sultanah Bahiyah Hospital, Alor Setar, Kadah, Malaysia|Sultan Abdul Halim Hospital, Sungai Petani, Kedah, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Ipoh, Perak, Malaysia|Taiping Hospital, Taiping, Perak, Malaysia|Tuanku Fauziah Hospital, Kangar, Perlis, Malaysia|Pulau Pinang Hospital, George Town, Pulau Pinang, Malaysia|Lahad Datu Hospital, Tawau, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Sungai Buloh Hospital, Shah Alam, Selangor, Malaysia|Permai Hospital, Kempas, Malaysia|Kepala Batas Hospital, Kepala Batas, Malaysia|Kuala Kangsar Hospital, Kuala Kangsar, Malaysia|Kuala Lumpur Hospital, Kuala Lumpur, Malaysia|Sultanah Nur Zahirah, Kuala Terengganu, Malaysia|Melaka Hospital, Melaka, Malaysia|Putrajaya Hospital, Putrajaya, Malaysia|Duchess of Kent Hospital, Sandakan, Malaysia|Low Risk COVID-19 Quarantine & Treatment Centre - Malaysia Agro Exposition Park Serdang (MAEPS), Serdang, Malaysia|Sg Siput Hospital, Sungai Siput, Malaysia|Tumpat Hospital, Tumpat, Malaysia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment
  • Enrollment - 500
  • Age - 50 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Number of Patients who Progressed to Severe Disease (Clinical stage 4 or 5)|Time Required for Patients on Treatment Arm to Progressed to Severe Disease (Clinical stage 4 or 5)|Mortality|Number of Participants with Complete Resolution of Symptoms by day 5 of Enrolment|Chest Radiograph Changes Pertaining to COVID-19 by Day 5 of Enrolment|Changes in Serum Absolute Lymphocyte Count|Changes in Serum Absolute Neutrophil Counts|Changes in Serum C-Reative Protein (CRP)|Changes in Serum Creatinine|Changes in Serum Alanine Aminotransferase (ALT)|Numbers of Participants Admitted to the Intensive Care Unit|Numbers of Participants who Require Mechanical Ventilation|The Length of Hospital Stay (in Calendar days)|Treatment-Related Adverse Events as Assessed by CTCAE v4.0
NCT05076253 Efficacy of Ivermectin in COVID-19 Completed Phase 1|Phase 2 Sep/01/2021 Dec/01/2021
  • Alternative id - 171/64
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Thananda Trakarnvanich, Bangkok, Thailand
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 72
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Viral clearance of SARS- CoV-2 intervention|Duration of hospitalization|frequency of clinical worsening|Mechanical ventilation|Mortality rate
NCT04527211 Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Not yet recruiting Phase 3 Sep/07/2020 Dec/16/2020
  • Alternative id - Epi1JaveCali
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Pontificia Universidad Javeriana, Cali, Valle Del Cauca, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 550
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical development of covid-19 disease during the intervention period|Seroconversion|Hospitalization requirement|Intensive Care Unit Requirement|Safety of the intervention
NCT04779047 Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. Recruiting Phase 4 Oct/01/2020 Apr/05/2021
  • Alternative id - REC-H-PhBSU-21011
  • Interventions - Drug: Remdesivir|Drug: Hydroxychloroquine|Drug: Tocilizumab|Drug: Lopinavir/ Ritonavir|Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Beni-suef University, Banī Suwayf, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years to 88 Years   (Adult, Older Adult)
  • Outcome measures - Percentage of clinical cure in each arm
NCT04435587 Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection Recruiting Phase 4 Jul/13/2020 Nov/01/2021
  • Alternative id - 323/2563 (IRB3)
  • Interventions - Drug: Ivermectin Pill|Drug: Combined ART/hydroxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Siriraj Hospital, Bangkok Noi, Bangkok, Thailand|Siriaj Hospital, Bangkok, N/A = Not Applicable, Thailand|Sireethorn Nimitvilai, Amphoe Maueng, Nakhonpathom, Thailand|Golden Jubilee Medical Center, Phutthamonthon District, Nakhonpathom, Thailand
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Adverse event rates|Efficacy for shortening duration of SAR-CoV2 detection by PCR|Antibody detection rates
NCT04381884 Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19 Completed Phase 2 May/18/2020 Sep/29/2020
  • Alternative id - IVM-AR-1
  • Interventions - Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital de Cuenca Alta, Cañuelas, Buenos Aires, Argentina|Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina|Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aires, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 45
  • Age - 18 Years to 69 Years   (Adult, Older Adult)
  • Outcome measures - Reduction in SARS-CoV-2 viral load|Number of patients with partial or complete response in COVID-19 clinical symptoms|Number of patients with worsening in the clinical condition|Number of patients with adverse events as a measure of safety and tolerability|Ivermectin concentrations measured in plasma|Evaluation of reactivity of the antibodies against SARS-CoV-2
NCT04425850 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 Completed Jun/01/2020 Aug/10/2020
  • Alternative id - IVERCAR
  • Interventions - Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)
  • Study type - Observational
  • Study results - Has Results
  • Locations - Hospital Eurnekian, Buenos Aires, Argentina
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 229
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Infected Subjects|Adverse Events Other Than Those Resulting From Contagion or Disease Progression
NCT04399746 Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 Completed Not Applicable Mar/15/2020 Jun/10/2020
  • Alternative id - IvAzCol
  • Interventions - Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Outpatient treatment, Mexico City, Mexico
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Viral clearance|Symptoms duration|SpO2|SpO2/FiO2
NCT04447235 Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection Recruiting Phase 2 Jul/23/2020 Feb/01/2021
  • Alternative id - NP 1677/20
  • Interventions - Drug: Placebo|Drug: Ivermectin|Drug: Losartan
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Instituto do Cancer do Estado de Sao Paulo, SAo Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 176
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of severe complications due COVID-19 infection|Incidence of Severe Acute Respiratory Syndrome|Adverse events|Overall survival
NCT04482686 Trial of Combination Therapy to Treat COVID-19 Infection Active, not recruiting Phase 1 Dec/09/2020 Jul/01/2022
  • Alternative id - PRG-049
  • Interventions - Drug: Ivermectin|Drug: Doxycycline Hcl|Dietary Supplement: Zinc|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ProgenaBiome, Ventura, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 31
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Non-Infectivity by RT-PCR|Time to Symptom progression in days as measured by NEWS scoring system (National Early Warning Score)|Time to Symptom improvement as measured by NEWS scoring system (National Early Warning Score)|Efficacy of Treatment as measured by Titer|Efficacy of Treatment as measured by RT-PCR|Safety of Treatment as Measured by D-Dimer|Safety of Treatment as Measured by Pro-Calcitonin|Safety of Treatment as Measured by C-Reactive Protein|Safety of Treatment as Measured by Ferritin|Safety of Treatment as Measured by Liver Enzymes|Safety of Treatment as Measured by Complete Blood Count|Safety of Treatment as Measured by Electrolyte Levels|Safety of Treatment as Measured by Treatment Related Adverse Events
NCT05231603 Ivermectin for Post Exposure Prophylaxis of Covid-19 Recruiting Phase 3 Feb/16/2022 Jun/30/2022
  • Alternative id - NMRR-21-1371-60569
  • Interventions - Drug: Ivermectin|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - KK Bandar Sg Petani, Sungai Petani, Kedah, Malaysia|KK Seberang Jaya, Butterworth, Penang, Malaysia|KK Bagan Serai, Bagan Serai, Perak, Malaysia|KK Greentown, Ipoh, Perak, Malaysia|KK Karai, Kuala Kangsar, Perak, Malaysia|KK Ayer Tawar, Sitiawan, Perak, Malaysia|KK Tanjung Malim, Slim River, Perak, Malaysia|KK Simpang, Taiping, Perak, Malaysia|KK Tapah, Tapah, Perak, Malaysia|KK Kangar, Kangar, Perlis, Malaysia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Covid-19 cases|CT value in Covid-19
NCT04351347 The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment Recruiting Phase 2|Phase 3 Jun/16/2020 Dec/01/2030
  • Alternative id - ivermecin covid
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Tanta University, Tanta, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - Child, Adult, Older Adult
  • Outcome measures - Number of patients with improvement or died
NCT04602507 Ivermectin in Adults With Severe COVID-19. Terminated Phase 2 Dec/10/2020 Dec/09/2021
  • Alternative id - ECA-COVID-CES
  • Interventions - Drug: Ivermectin|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinica CES, Medellín, Antioquia, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 75
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Admission to the intensive care unit.|Hospital length of stay.|Mortality rate.|ICU length of stay.|Length of stay in ventilator time.|Adverse effects of ivermectin.
NCT05060666 Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen] Not yet recruiting Phase 3 Nov/01/2021 Mar/01/2022
  • Alternative id - PREVENT-COVID|2021-002445-15
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
  • Enrollment - 412
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 disease|Adverse events and side effects|Type, number and severity of symptoms|Severity of the COVID-19 disease
NCT04429711 Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 Recruiting Not Applicable May/12/2020 Oct/31/2020
  • Alternative id - SHEBA-20-7156-ES-CTIL
  • Interventions - Drug: Ivermectin Oral Product
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Sheba Medical Center, Ramat-Gan, Israel
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Viral clearance at day 6|Viral shedding duration|Symptoms clearance time
NCT04681053 Inhaled Ivermectin and COVID-19 Recruiting Phase 3 Feb/25/2021 Dec/31/2021
  • Alternative id - R.20.11.1090.R1
  • Interventions - Drug: Ivermectin Powder
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mansoura Faculty of Medicine, Mansoura, Dakahlyia, Egypt
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Rate of virological cure by Rt -PCR for COVID -19 using ivermectin when compared to standard treatment|resolution of pneumonia
NCT04510233 Ivermectin Nasal Spray for COVID19 Patients Not yet recruiting Phase 2 Sep/01/2020 Dec/01/2020
  • Alternative id - IvrInh
  • Interventions - Drug: Ivermectin nasal|Drug: Ivermectin oral|Other: standard care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - PCR of SARS-Cov2 RNA
NCT04407507 Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms Completed Phase 2 Jul/01/2020 Jan/29/2021
  • Alternative id - SARS-COV-IverMX-01
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Investigacion Biomédica para el Desarrollo de Fármacos S.A. de C.V., Zapopan, Jalisco, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment
  • Enrollment - 66
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Participants With a Disease Control Status Defined as no Disease Progression to Severe.|SARS-CoV-2 Viral Load, at 5 and 14 Days|Presence and Frequency of Symptoms Associated With the COVID-19 Disease
NCT04673214 Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment Completed Phase 3 Dec/16/2020 Feb/25/2021
  • Alternative id - R-2020-785-176
  • Interventions - Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Drug: Azithromycin / Ribaroxaban / Paracetamol
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Alma Italia Guerrero Martinez, Mexico, Distrito Federal, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 114
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.|Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS
NCT04405843 Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial) Completed Phase 2|Phase 3 Jul/14/2020 Dec/21/2020
  • Alternative id - ScDi823|IVE-PA
  • Interventions - Drug: Ivermectin Oral Product|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Centro de Estudios en Infectología Pediátrica, Cali, Valle, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 476
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to event|Clinical condition on day 2|Clinical condition on day 5|Clinical condition on day 8|Clinical condition on day 11|Clinical condition on day 15|Clinical condition on day 21|Proportion of subjects with additional care|Proportion of subjects who die|Duration of additional care|Adverse events|Proportion of subjects who discontinue intervention|Duration of fever
NCT04723459 Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff Recruiting Not Applicable Jan/23/2021 Mar/28/2021
  • Alternative id - SVU MED CIT0 23 4 21 1 121
  • Interventions - Other: ivermectin impregnated mask
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Zaky Aref, Qina, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 150
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of persons in each group who Complain of any suspected Symptoms|Number of persons in each group who are diagnosed as COVID-19 patients
NCT04886362 Ivermectina Colombia (IVERCOL) Not yet recruiting Phase 2|Phase 3 Jul/01/2021 Dec/01/2021
  • Alternative id - IVERCOL01
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 966
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Composite Outcome|Hypoxemia (oxygen saturation ≤90%) and need for supplemental oxygen in home care program.|Need for hospitalization including general bed, ICU or ICU.|Death from any cause.|Proportion of patients with 4 or more points on the WHO scale (8-point ordinal scale).|Number of days with supplemental oxygen requirement.|Number of days on ICU management.|Number of days on endotracheal intubation (IOT).|Number of days of hospitalization.|Number and type of serious and non-serious adverse events.
NCT05155527 A Double-blind Randomized Controlled Trial of Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients Not yet recruiting Phase 2 Dec/01/2021 Jun/01/2022
  • Alternative id - CREC067/64BR-MED46
  • Interventions - Drug: Ivermectin Tablets|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - The rate of SARS-CoV-2 viral clearance|Mortality rate|Progression to severe disease|Duration of admission|Oxygen requirement|Proportions of SARS-CoV-2 viral clearance
NCT04384458 Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis Recruiting Not Applicable Jul/20/2020 Apr/01/2021
  • Alternative id - HCQ+IVM
  • Interventions - Drug: Hydroxychloroquine|Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 400
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Proportion of participants in whom there was a positivity for SARS-CoV-2.|Participants who developed mild, moderate, or severe forms of COVID-19.|Measurement of the QT interval.|Widening of the corrected QT interval or with changes in heart rate on the ECG.|Comparison of hematological and biochemical parameters.|Occurrence of adverse events.|Assessment of COVID-19 symptom severity.|Proportion of participants who discontinue study intervention.|Proportion of participants who required hospital care.|Proportion of participants who required mechanical ventilation.
NCT04360356 Ivermectin and Nitazoxanide Combination Therapy for COVID-19 Not yet recruiting Phase 2|Phase 3 May/01/2020 Dec/01/2020
  • Alternative id - IVR/NTZ
  • Interventions - Combination Product: Ivermectin plus Nitazoxanide|Other: Standard Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Number of Patients with COVID-19-negative PCR|Number of patients with improved respiratory rate|Number of patients with improved PaO2|Number of patients with normalized Serum IL6|Number of patients with normalized Serum TNFα|Number of patients with normalized Serum iron|Number of patients with normalized Serum ferritin|Number of patients with normalized International normalized ratio "INR" for prothrombin time|Number of patients with normalized complete blood count "CBC"|The Mortality rate among treated patients
NCT04373824 Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study Recruiting Not Applicable Apr/25/2020 Jul/25/2020
  • Alternative id - MHC-COVID-19- INV- ACT-BHR
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Max Super Speciality hospital, Saket (A unit of Devki Devi Foundation), New Delhi, Delhi, India
  • Study designs - Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - effect of Ivermectin on eradication of virus.
NCT04446104 A Preventive Treatment for Migrant Workers at High-risk of COVID-19 Completed Phase 3 May/13/2020 Aug/31/2020
  • Alternative id - 2020/00561
  • Interventions - Drug: Hydroxychloroquine Sulfate Tablets|Drug: Ivermectin 3mg Tab|Drug: Zinc|Drug: Povidone-Iodine|Dietary Supplement: Vitamin C
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Tuas South Dormitory, Singapore, Singapore
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 4257
  • Age - 21 Years to 60 Years   (Adult)
  • Outcome measures - Laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Acute respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Febrile respiratory illness in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of hospitalization for COVID-19 and non-COVID-19 related indications in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Duration of oxygen supplementation and mechanical ventilation in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Length of hospital stay in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Rate of laboratory-confirmed COVID-19 in treatment arms (hydroxychloroquine, ivermectin, zinc and povidone iodine)|Adverse events and serious adverse events in control arm (Vitamin C)|Drug discontinuation due to adverse events in control arm (Vitamin C)
NCT04885530 ACTIV-6: COVID-19 Study of Repurposed Medications Recruiting Phase 3 Jun/08/2021 Mar/01/2023
  • Alternative id - Pro00107921|3U24TR001608-05W1
  • Interventions - Drug: Ivermectin|Drug: Fluvoxamine|Drug: Fluticasone|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Lamb Health, LLC, Gilbert, Arizona, United States|First Care Medical Clinic, Mesa, Arizona, United States|Trident Health Center, Peoria, Arizona, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Assuta Family Medical Group APMC, North Hollywood, California, United States|Doctors Medical Group of Colorado Springs, P.C., Colorado Springs, Colorado, United States|Pine Ridge Family Medicine Inc., Colorado Springs, Colorado, United States|Tabitha B. Fortt, M.D., LLC, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Lupus Foundation of Gainesville, Gainesville, Florida, United States|University of Florida Health, Gainesville, Florida, United States|University of Florida-JAX-ASCENT, Jacksonville, Florida, United States|Sunshine Walk In Clinic, Lake Mary, Florida, United States|Lakeland Regional Medical Center, Lakeland, Florida, United States|University of Miami, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Innovation Clinical Trials Inc., Palmetto Bay, Florida, United States|Lice Source Services Plantation, Plantation, Florida, United States|Premier Health, Saint Petersburg, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|UF Health Precision Health Research, The Villages, Florida, United States|Emory Healthcare, Atlanta, Georgia, United States|Essential Medical Care, Inc., College Park, Georgia, United States|David Kavtaradze MD, Inc., Cordele, Georgia, United States|Elite Family Practice, Douglasville, Georgia, United States|Christ the King Health Care, P.C., Loganville, Georgia, United States|Miller Family Practice, LLC, Macon, Georgia, United States|Olivo Wellness Medical Center, Chicago, Illinois, United States|NorthShore Medical Group, Evanston, Illinois, United States|Advanced Medical Care, Ltd, Lake Zurich, Illinois, United States|Franciscan Health Michigan City, Michigan City, Indiana, United States|Del Pilar Medical and Urgent Care, Mishawaka, Indiana, United States|University of Kansas - Wichita, Wichita, Kansas, United States|A New Start II, LLC, Central City, Kentucky, United States|University Medical Center- New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Jadestone Clinical Research, LLC, Rockville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Health Quality Primary Care, Lawrence, Massachusetts, United States|Ananda Medical Clinic, Dearborn, Michigan, United States|GFC of Southeastern Michigan, PC, Detroit, Michigan, United States|Romancare Health Services, Detroit, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Missouri - Columbia, Columbia, Missouri, United States|Focus Clinical Research Solutions, Bayonne, New Jersey, United States|Raritan Bay Primary Care & Cardiology Associates, Matawan, New Jersey, United States|Mediversity Healthcare, Turnersville, New Jersey, United States|Geriatrics and Medical Associates, Clinton, New York, United States|Weill Cornell Medical College, New York, New York, United States|Spinal Pain and Medical Rehab, PC, Yonkers, New York, United States|Vaidya MD PLLC, Clayton, North Carolina, United States|Maria Medical Center, PLLC, Dunn, North Carolina, United States|Duke Clinical Research Institute, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|TriHealth, Inc, Montgomery, Ohio, United States|The Heart and Medical Center, Durant, Oklahoma, United States|Hugo Medical clinic, Hugo, Oklahoma, United States|Temple University Medical Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Clinical Trials Center of Middle TN, Franklin, Tennessee, United States|Rapha Family Wellness, Hendersonville, Tennessee, United States|Medical Specialists of Knoxville, Knoxville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Express Family Clinic, Allen, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Family Practice Doctors P.A., Humble, Texas, United States|University Diagnostics and Treatment Clinic, Pasadena, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 15000
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of hospitalizations as measured by patient reports.|Number of deaths as measured by patient reports|Number of symptoms as measured by patient reports|Change in COVID Clinical Progression Scale|Number of hospitalizations as measured by patient reports|Number of Symptom Resolutions as measured by patient reports|Change in Quality of Life (QOL) as measured by the PROMIS-29|Composite score of hospitalizations, urgent care visits, and emergency room visits as measured by patient reports
NCT04712279 The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial) Not yet recruiting Phase 2|Phase 3 Jan/25/2021 Apr/20/2021
  • Alternative id - CORPO-DRUG-SARSCoV2-001
  • Interventions - Drug: Ivermectin 0.6mg/kg/day|Drug: Ivermectin 1.0mg/kg/day|Drug: Placebo|Drug: Hydroxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 294
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death] [Time Frame: Day 7]|Time-to-recovery|Viral load|Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of pressors use|Proportion of deaths|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to Day 1)|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to Day 1)|Proportion of increased d-dimer (defined as d-dimer > 500 mg/dL)|Disease duration|Change in viral load from baseline to Day 5
NCT04768179 Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients Not yet recruiting Phase 2|Phase 3 Feb/19/2021 Sep/30/2021
  • Alternative id - IVCOM PROTOCOL VERSION 03
  • Interventions - Drug: 3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 490
  • Age - 18 Years to 64 Years   (Adult)
  • Outcome measures - SARS COV 2 Viral clearance|World Health Organization COVID-19 ordinal improvement score|Clinical recovery|Spectrum and severity of adverse events|Maximum Plasma concentration|Minimum Plasma concentration|Area Under the Curve
NCT04701710 Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan Completed Phase 1|Phase 2 Oct/15/2020 Dec/31/2020
  • Alternative id - 5076-410-CH2020
  • Interventions - Drug: Ivermectin / Iota-Carrageenan
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SI.PRO.SA, Ministerio de Salud Pública, Tucumán, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 300
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - Pearson's Chi-square and proportion test.|Odd Ratio, probabilistic test|Logistic regression test
NCT04729140 An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization Recruiting Phase 4 Dec/28/2020 Mar/28/2022
  • Alternative id - COVIVER-OUT PLUS
  • Interventions - Drug: Ivermectin Tablets|Drug: Doxycycline Tablets|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - MAX HEALTH, Subsero Health 2055 Wood Street, Suite 100, Sarasota, Florida, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Decreased admission rate to the hospital secondary to respiratory illness related to COVID-19|Decrease in total duration of symptoms secondary to respiratory illness related to COVID-19|Assessment of White Blood Cell Count|Assessment of Hemoglobin level|Assessment of Hematocrit level|Assessment of Platelet Count|Assessment of Sodium level|Assessment of Potassium level|Assessment of Chloride level|Assessment of Carbon Dioxide level|Assessment of Blood Urea Nitrogen level|Assessment of Creatinine level|Assessment of Calcium level|Assessment of Glucose level|Assessment of Total Bilirubin level|Assessment of Total Protein level|Assessment of Albumin level|Assessment of Aspartate Aminotransferase level|Assessment of Alanine Aminotransferase level|Assessment of Alkaline Phosphatase level|Assessment of Ferritin|Assessment of D-dimer|Assessment of Creatine Phosphokinase|Assessment of C-Reactive Protein|Assessment of Prothrombin Time and International Normalized Ratio|Assessment of activated Partial Thromboplastin Time|Assessment of Fibrinogen Activity|Assessment of Interleukin 6 level|Assessment of Interleukin 6 receptor level|Assessment of Tumor Necrosis Factor Alpha level|Assessment of Tumor Necrosis Factor Alpha Receptor level|Mortality|Measurement of Participants with Medication Side Effects|Measurement of Participants with new onset Shortness of Breath or Changes in Shortness of Breath Severity|Measurement of Participants Pulse Oximetry readings on room air|Measurement of Participants with new onset Red Eyes or Changes in Red Eyes Severity|Measurement of Participants with new onset Chills or Changes in Chills Severity|Measurement of Participants with new onset Runny Nose or Changes in Runny Nose Severity|Measurement of Participants with new onset Sore Throat or Changes in Sore Throat Severity|Measurement of Participants with new onset Loss of Smell or Changes in Severity of in Loss of Smell|Measurement of Participants with new onset Loss of Taste or Changes in Severity of Loss of Taste|Measurement of Participants with new onset Body Aches or Body Pains or Changes in Body Aches or Body Pains Severity|Measurement of Participants with new onset Diarrhea or Changes in Diarrhea Severity|Measurement of Participants with new onset Headaches or Changes in Headaches Severity|Measurement of Participants with new onset Anxiety or Changes in Anxiety Severity|Measurement of Participants with new onset Fatigue or Changes in Fatigue Severity|Measurement of Participants with new onset Trouble Concentrating or Changes in Trouble Concentrating Severity|Measurement of Participants with new onset Cough or Changes in Cough Severity|Measurement of Participants with new onset Vomiting or Changes in Vomiting Severity|Measurement of Participants with new onset Nausea or Changes in Nausea Severity|Measurement of Participants with new onset Feelings of Hopelessness or Changes in Feelings of Hopelessness severity|Measurement of Participants with new onset feelings of Depression or Changes in feelings of Depression severity|Measurement of Participants with new onset Fever or Changes in Fever Severity|Measurement of Participants with new onset Moving Slowly or Changes in the Severity of Moving Slowly|Measurement of Participants with new onset Speaking Slowly or Changes in the Severity of Speaking Slowly|Measurement of Participants with new onset Feelings of Restlessness or Changes in the Severity of Feelings of Restlessness|Measurement of Participants with new onset Thoughts of Better Off Being Dead or Changes in the Severity of Thoughts of Better Off Being Dead|Measurement of Participants with new onset Thoughts of Hurting Yourself or Changes in the Severity of Thoughts of Hurting Yourself|Measurement of Participants with new onset Loss of Interest in Doing Things or Changes in the Severity of Loss of Interest in Doing Things|Measurement of Participants with new onset Loss of Pleasure in Doing Things or Changes in the Severity of Loss of Pleasure in Doing Things|Measurement of Participants with new onset Trouble Falling Asleep or Changes in the Severity of Trouble Falling Asleep|Measurement of Participants with new onset Trouble Staying Asleep or Changes in the Severity of Trouble Staying Asleep|Measurement of Participants with new onset Unmentioned Negative Impacts of COVID 19 infection or Changes in the Severity of these Negative Impacts of COVID 19 infection
NCT05045937 Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 Not yet recruiting Sep/20/2021 Sep/20/2023
  • Alternative id - Ivermectin Treatment Study #1
  • Interventions - Drug: Ivermectin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Patrick Robinson MD LLC, San Antonio, Florida, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 1000
  • Age - 12 Years to 110 Years   (Child, Adult, Older Adult)
  • Outcome measures - Complete recovery from COVID-19 with resolution of symptoms|Admission to a hospital for further advanced treatment
NCT04714515 Montelukast - a Treatment Choice for COVID-19 Completed Feb/20/2020 Apr/20/2020
  • Alternative id - 01032020-7
  • Interventions - Drug: Montelukast|Drug: Hydroxychloroquine|Drug: Ivermectin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China|Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 150
  • Age - 20 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Patients admittance to ICU|Length of total stay at the hospital|Alleviating the symptoms of COVID-19|Interleukin levels
NCT04739410 Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients Completed Phase 4 May/01/2020 Jun/30/2020
  • Alternative id - IRB#FMH-07-2020-IRB-766-M
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Aijaz Zeeshan Khan Chachar, Lahore, Punjab, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Resolution of symptoms|Progression of the disease
NCT05041907 Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) Recruiting Phase 2 Sep/30/2021 Aug/01/2023
  • Alternative id - VIR21001
  • Interventions - Drug: Favipiravir|Drug: Monoclonal antibodies|Drug: Ivermectin|Other: No treatment|Drug: Remdesivir
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Universidade Federal de Minas Gerais, Minas Gerais, Brazil|Vajira hospital, Bangkok, Thailand|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|Bangplee Hospital, Samut Prakan, Thailand
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 750
  • Age - 18 Years to 50 Years   (Adult)
  • Outcome measures - Rate of viral clearance for repurposed drugs|Rate of viral clearance of positive control (monoclonal antibodies) over time relative to the negative control|Rate of viral clearance for small novel molecule drugs|Viral kinetic levels in early COVID-19 disease|Number of antiviral treatment arms that show a positive signal (>90% probability of >5% acceleration in viral clearance)|Rates of viral clearance by treatment arm, as compared against REGN-COV2 (monoclonal antibody cocktail)
NCT05269030 Ivermectin Nasal Drops in Post COVID Parosmia Not yet recruiting Phase 2 Apr/01/2022 Dec/01/2022
  • Alternative id - 1/2022 PHAR
  • Interventions - Drug: Ivermectin Topical|Drug: Budesonide Nasal
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Menoufia Faculty of Medicine, Shibīn Al Kawm, Menoufia, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Comparison between the pre and post treatment values|Comparison between case and control groups regarding the post treatment results|Assessment of the side effects of Ivermectin nasal drops
NCT04646109 Ivermectin for Severe COVID-19 Management Completed Phase 3 May/11/2020 Sep/02/2020
  • Alternative id - IVMC_03
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Afyonkarahisar Health Science University, Afyonkarahisar, Turkey|Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey|Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey|Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 66
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Gender Distribution of the Patients|Age Distribution of the Patients|Percentage of Patients With Accompanying Diseases|Percentage of Patients With Baseline Clinical Symptoms|Body Temperature Means of the Patients|Heart Rate Means of the Patients|Respiratory Rate Means of the Patients|Systolic and Diastolic Pressure Means of the Patients|Number of Participants With Clinical Response|Changes in Oxygen Saturation (SpO2) Values|Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)|Changes in Serum Lymphocyte Counts|Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)|Changes in Serum Ferritin Levels|Changes in Serum D-dimer Levels|Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism|Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Mortality|Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity
NCT04529525 Ivermectin to Prevent Hospitalizations in COVID-19 Completed Phase 2|Phase 3 Aug/19/2020 Feb/22/2021
  • Alternative id - IVERCORCOVID19MSPICC
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ministry of Public Health of the Province of Corrientes, Corrientes, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 501
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of Hospitalization of medical cause in patients with COVID-19 in each arm|Time to hospitalization|Percentage of Use of invasive mechanical ventilation support in each arm|Time to invasive mechanical ventilation support|Percentage of dialysis in each arm|All-cause mortality|Negative of the swab at 3±1 days and 12±2 days after entering the study|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])
NCT04434144 A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh Completed May/02/2020 Jun/05/2020
  • Alternative id - 10000918
  • Interventions - Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 116
  • Age - 16 Years to 80 Years   (Child, Adult, Older Adult)
  • Outcome measures - Number of participants with "treatment success" determine by a negative RT PCR for COVID19.|Number of participants with "adverse effects" determined by the existence of the pharmacological side effects of the particular drug during treatment.
NCT04391127 Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection Completed Phase 3 May/04/2020 Nov/06/2020
  • Alternative id - 2020-A-09
  • Interventions - Drug: Hydroxychloroquine|Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Jose Manuel Arreola Guerra, Aguascalientes, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 108
  • Age - 16 Years to 90 Years   (Child, Adult, Older Adult)
  • Outcome measures - Mean days of hospital stay|Rate of Respiratory deterioration, requirement of invasive mechanical ventilation or dead|Mean of oxygenation index delta|Mean time to viral PCR negativization
NCT04894721 Prophylaxis for COVID-19: Ivermectin in Close Contacts of COVID-19 Cases (IVERNEX-TUC) Completed Phase 2|Phase 3 Jun/01/2021 Oct/01/2021
  • Alternative id - 5077/410 CH 2020
  • Interventions - Drug: Ivermectin|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SI.PRO.SA, Ministerio de Salud Pública, Tucumán, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
  • Enrollment - 172
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - Number of subjects who were diagnosed with COVID-19 in EG and CG (Negative polymerase chain reaction - real-time).|Contagion risk.|Prophylactic effect associated with patient's preexisting comorbidity
NCT04438850 COVidIVERmectin: Ivermectin for Treatment of Covid-19 Terminated Phase 2 Jul/31/2020 Jun/08/2021
  • Alternative id - cover_1
  • Interventions - Drug: Ivermectin|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - IRCCS Sacro Cuore Don Calabria hospital, Negrar, Verona, Italy|Policlinico S. Orsola, Bologna, Italy|Ospedale Luigi Sacco, Milan, Italy|Ospedale di Rovereto, Rovereto, Italy|Ospedale Amedeo di Savoia, Turin, Italy
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 93
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - SADR|Viral load|Trend viral load|Clinical resolution|Viral clearance|Virological clearance|hospitalization rate|Severity score
NCT04834115 Efficacy of Ivermectin in Outpatients With Non-severe COVID-19 Recruiting Phase 3 Nov/17/2020 May/30/2021
  • Alternative id - PINV20-387
  • Interventions - Drug: Ivermectin Tablets|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Facultad de Ciencias Médicas - Universidad Nacional de Asunción, Asunción, Paraguay
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of patients with hospitalization criteria|Proportion of patients with COVID-19 signs and symptoms|Proportion of cohabitants who had COVID-19 after the index case|Drug-related adverse events|Levels of IgG for SARS-CoV-2
NCT04460547 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic Not yet recruiting Jul/25/2020 Sep/20/2020
  • Alternative id - COAHS
  • Interventions - Drug: Convalescent Plasma Transfusion|Drug: Hydroxychloroquine|Drug: DAS181|Drug: Ivermectin|Drug: Interferon Beta-1A
  • Study type - Observational
  • Study results - No Results Available
  • Locations -
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 200
  • Age - 1 Year and older   (Child, Adult, Older Adult)
  • Outcome measures - Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.
NCT04747678 Adverse Effects of Ivermectin Used in Egypt During COVID-19 Enrolling by invitation Feb/03/2021 Mar/01/2021
  • Alternative id - ahmed19782020
  • Interventions - Drug: Ivermectin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Ahmed Mansour, Shibīn Al Kawm, Menoufia, Egypt
  • Study designs - Observational Model: Case-Crossover|Time Perspective: Cross-Sectional
  • Enrollment - 200
  • Age - 16 Years to 80 Years   (Child, Adult, Older Adult)
  • Outcome measures - all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020|all data will be arranged according to time and dose manner
NCT04510194 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Active, not recruiting Phase 3 Jan/01/2021 Feb/01/2023
  • Alternative id - GIM-2020-29324
  • Interventions - Drug: Metformin|Drug: Placebo|Drug: Fluvoxamine|Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Olive View UCLA Medical Center, Sylmar, California, United States|University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center, Aurora, Colorado, United States|New West Physicians, Golden, Colorado, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|American Health Network of Indiana, Greenfield, Indiana, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1350
  • Age - 30 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Clinical Progression|Maximum symptom severity|Clinical Progression Scale|Time to meaningful recovery|Laboratory Outcome Subsidy - Viral Load|Laboratory Outcome Subsidy|Laboratory Outcome Subsidy - Microbiome|Portion of participants with Post-Acute Sequelae of SARS-CoV-2 infection (PASC)
NCT04407130 Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection. Completed Phase 2 Jun/16/2020 Nov/20/2020
  • Alternative id - PR-20039
  • Interventions - Drug: Ivermectin + Doxycycline + Placebo|Drug: Ivermectin + Placebo|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Icddr,B, Dhaka, Bangladesh
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 72
  • Age - 40 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Virological clearance|Remission of fever|Remission of cough|Patients requiring oxygen|Patients failing to maintain SpO2 >93% despite oxygenation|Number of days on oxygen support|Duration of hospitalization|All causes of mortality
NCT04937569 Ivermectin Versus Standard Treatment in Mild COVID-19 Not yet recruiting Phase 3 Jul/01/2021 Nov/01/2021
  • Alternative id - AssiutU-Ivercom
  • Interventions - Drug: Ivermectin Tablets
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Aliae AR Mohamed-Hussein, Assiut, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1644
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Rate of ICU admission in mild COVID-19 cases|Time to clinical improvement.|Overall clinical state, using the 7-point ordinal scale|The duration of critical care interventions in each arm of the study.|• Proportion of subjects who develop adverse events associated with the study drug.
NCT04951362 Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia Recruiting Phase 2|Phase 3 Apr/20/2021 Sep/12/2021
  • Alternative id - SVU MED CIT0 23 4 21 1 122
  • Interventions - Drug: ivermectin nasal spray
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Zaky Aref, Qina, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 117
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - regaining of smell
NCT04392427 New Antiviral Drugs for Treatment of COVID-19 Not yet recruiting Phase 3 Oct/01/2020 May/01/2022
  • Alternative id - 20.05.69
  • Interventions - Drug: Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days :
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mansoura University, Mansoura, Select A State Or Province, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - negative test result for COVID-19
NCT04784481 Ivermectin Reproposing for Mild Stage COVID-19 Outpatients Completed Phase 1|Phase 2 Sep/20/2020 Jan/18/2021
  • Alternative id - 5077-410-CH2020
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SI.PRO.SA, Ministerio de Salud Pública, Tucumán, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 254
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Proportion test|Odd Ratio|Odd Ratio and logistic regression test
NCT04374019 Novel Agents for Treatment of High-risk COVID-19 Positive Patients Terminated Phase 2 May/01/2020 Jan/12/2022
  • Alternative id - MCC-20-COVID-01-PMC
  • Interventions - Drug: Ivermectin|Drug: Camostat Mesilate|Dietary Supplement: Artemesia annua|Drug: Artesunate
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 13
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Clinical Deterioration|Change in Viral Load|Rate of Organ Failure|Progression to ICU Care or Ventilation|Number of Participants Who Had a Change in Clinical Status Measured by Decrease in COVID 7-point Ordinal Scale|Mortality|Rate of Severe Adverse Events|Number of Patients That Required Oxygen Supplementation|Number of Patients That Required Mechanical Ventilation|Number of Patients Who Required Vasopressors|Number of Patients Who Required ICU Services|Number of Patients That Required Hospitalization|Heart Function
NCT04425863 Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 Completed May/01/2020 Aug/30/2020
  • Alternative id - IDEA
  • Interventions - Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|Other: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|Other: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
  • Study type - Observational
  • Study results - Has Results
  • Locations - Hospital Eurnekian, Buenos Aires, Argentina
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 167
  • Age - 5 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Patients Who Improved Their Condition or Did Not Worsen it|ICU-treated Patients After 2-week Treatment|Mortality|Patients Needing Drug Dose Adjustment|Adverse Events
NCT05246072 Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients Recruiting Phase 4 Nov/01/2021 Feb/28/2022
  • Alternative id - FAMSU R 179 / 2021
  • Interventions - Drug: Ivermectin + colchicine|Drug: Colchicine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ain Shams University hospitals, Cairo, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - length of oxygen requirement
NCT05040724 Evaluation of the Impact of the Administration of Single Dose of Ivermectin in the Early Phase of COVID-19 Active, not recruiting Phase 3 May/28/2021 Jun/01/2022
  • Alternative id - 2020-005423-37
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - GHI Le Raincy Montfermeil, Montfermeil, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - negativation of the RT-PCR test on nasopharyngeal samples of SARS-CoV-2
NCT04523831 Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection Completed Phase 3 Jun/01/2020 Sep/10/2020
  • Alternative id - ERC-DMC/ECC/2020/117
  • Interventions - Drug: Ivermectin and Doxycycline|Drug: Standard of care
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Dhaka Medical College, Dhaka, Bangladesh
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Patients With Early Clinical Improvement|Number of Participants With Late Clinical Recovery|Number of Patients Having Clinical Deterioration.|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19
NCT04390022 Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial Completed Phase 2 Jul/31/2020 Oct/09/2020
  • Alternative id - SAINT
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Clinica Universidad de Navarra, Pamplona, Navarra, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 24
  • Age - 18 Years to 59 Years   (Adult)
  • Outcome measures - Proportion of Patients With a Positive SARS-CoV-2 PCR|Median Viral Load|Fever and Cough Progression|Seroconversion at Day 21|Proportion of Drug-related Adverse Events|Levels of IgG, IgM and IgA|Frequency of Innate Immune Cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells|Results From Cytokine Human Magnetic 30-Plex Panel
NCT04635943 Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19 Completed Phase 2 Aug/29/2020 Apr/30/2021
  • Alternative id - EC-CNTEI-014-2020
  • Interventions - Drug: Ivermectin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Nacional Cayetano Heredia, Lima, Peru
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 186
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Proportion of patients with a positive SARS-CoV-2 PCR.|Mean viral load|Fever and cough progression|Seroconversion at day 21|Proportion of drug-related adverse events|Levels of IgG, IgM and IgA|Frequency of innate immune cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T cells|Results from cytokine Human Magnetic 30-Plex Panel|Presence of intestinal helminths
NCT04703608 Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia Recruiting Phase 3 Jan/22/2021 Jul/01/2022
  • Alternative id - LEO 22628
  • Interventions - Drug: Ivermectin|Drug: ASP|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Mrcg@Lshtm, Fajara, Gambia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 1200
  • Age - 5 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Cohort 1 Index Case: Percentage of patients with COVID-19 associated mild disease/moderate pneumonia progressing to severe pneumonia [Time frame 14 days]|Cohort 1 Household contacts: Percentage of HH members that get infected with SARS-CoV-2 [Time frame 14 days]|Cohort 2: Percentage of COVID-19 associated severe pneumonia patients worsening their condition [Time frame at discharge or day 28 (whichever is first)]|Cohort1 Index cases: Days from recruitment to virological clearance [Time frame 28 days]|Days from recruitment until clinical recovery|- IgG geometric mean titre (GMT) at day 14 and 28 after recruitment [Time frame 14 days and 28 days]|Household contacts IgG geometric mean titre (GMT) at day 14 after recruitment [Time frame 14 days]|Percentage of HH members infected that develop COVID19 symptoms [Time frame 14 days]|Cohort 2 - Hours from recruitment to hospital discharge [Time frame at discharge]|- Hours of duration on oxygen supplementation [Time frame at discharge or day 28 (whichever is first)]|- Death ratio during hospitalization [Time frame at time of death]|- Death ratio at 28 days after enrolment [Time frame 28 days]|- Death ratio at 90 days after enrolment [Time frame 90 days]|- Occurrence of clinical thrombotic and embolic events (myocardial infarction, pulmonary embolus, deep venous thrombosis, cerebrovascular accidents). [Time frame 90 days]|- Occurrence of clinical episodes of gastrointestinal bleeding [Time frame 90 days]|- Change in CRP and D-Dimer levels between baseline (enrolment) and day 3-5 [Time frame 5 days]|- Persisting breathlessness at 28 days and 90 days after enrolment [Time frame 28 days/90 days ]|- Self-reported health at 28 days and 90 days [Time frame 28 days/ 90 days]
Export (.csv)